Prestige Consumer Healthcare to Acquire Breathe Right and Other Brands for $1.045 Billion, Boosting Portfolio and Revenue

summarizeSummary

Prestige Consumer Healthcare announced a definitive agreement to acquire the Breathe Right® brand and other OTC products for $1.045 billion in cash, a move expected to be immediately accretive to financials and expand its brand portfolio.

check_boxKey Events

• Major Acquisition Announced

  Prestige Brands, Inc., a wholly-owned subsidiary, entered into an Asset Purchase Agreement to acquire a portfolio of over-the-counter consumer health products, including Breathe Right® and other brands, from Foundation Consumer Brands, LLC.

• Significant Purchase Price

  The acquisition is valued at $1.045 billion in cash, or approximately $900 million net of anticipated tax benefits.

• Strong Financial Contribution

  The acquired portfolio generated approximately $200 million in revenue and $95 million in EBITDA over the twelve months ended December 31, 2025.

• Accretive to Financials

  The transaction is expected to be immediately accretive to Prestige's revenue, gross margins, EBITDA margins, earnings per share, and free cash flow.

auto_awesomeAnalysis

Prestige Consumer Healthcare's agreement to acquire the Breathe Right® brand and other OTC products for $1.045 billion is a highly significant strategic move. This acquisition, representing a substantial portion of the company's market capitalization, is expected to be immediately accretive to revenue, margins, EPS, and free cash flow. The addition of Breathe Right®, a leading brand in the 'better breathing' category, expands Prestige's portfolio into a new, attractive segment with international reach. While the transaction will initially increase the company's net leverage to approximately 4.0x, management has outlined a clear path to deleveraging to below 3.0x by fiscal 2028, supported by strong free cash flow generation. This strategic expansion, announced while the stock is trading near its 52-week low, could be a catalyst for investor re-evaluation, demonstrating management's commitment to growth and value creation through disciplined M&A.